Deal Note: Crowell & Moring Client Integrated BioTherapeutics Enters Into Exclusive Agreement with Chembio Diagnostics to Develop POC Diagnostic Tests for Ebola
Firm News | less than 1 min read | 10.27.14
Washington, D.C. – October 27, 2014: Crowell & Moring, LLP is representing Integrated BioTherapeutics, Inc. (IBT), a biotechnology company focused on the discovery of novel vaccines and therapeutics for emerging infectious diseases, as it enters into an exclusive agreement with Chembio Diagnostics, Inc., a leader in point-of-care (POC) diagnostic tests for infectious diseases. Under the terms of the agreement, Chembio will combine its patented DPP technology with IBT's proprietary Ebola reagents to develop POC diagnostic tests for Ebola and febrile illness. Chembio will have exclusive rights to any POC product developed through this agreement. Financial terms of the agreement were not disclosed.
Insights
Firm News | 3 min read | 05.01.24
Crowell Continues Corporate Expansion in Chicago
Crowell & Moring announced today that partner Elaine Taussig is joining the firm’s Corporate group and partner Tom Williams is joining the firm’s Corporate and IP groups in Chicago from Neal, Gerber & Eisenberg.
Firm News | 2 min read | 04.30.24
Firm News | 2 min read | 04.26.24
The Los Angeles Business Journal Names Valerie Goo to Top 100 Lawyers 2024
Firm News | 2 min read | 04.18.24
Global Public Affairs Executive Mark Elliot Joins Crowell & Moring International